Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23)
- Target
- ADAM23
- Molecular classification
- Membrane-anchored protein, Disintegrin protein, Metalloprotease-like, Adhesion molecule
01
Overview
Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23) is a member of the ADAM family, structurally related to snake venom disintegrins. Unlike most ADAMs, ADAM23 is non-catalytic: its metalloproteinase-like domain lacks key residues for enzymatic activity. It is predominantly expressed in the brain and functions mainly as an adhesion molecule through a specific interaction with the αvβ3 integrin, promoting neural cell attachment by an RGD-independent mechanism. This protein has implications in cell adhesion, neurogenesis, and tumor progression, especially of neural origin. Evidence suggests ADAM23 is a ligand for integrins and may be involved in mechanisms relevant to cancer and nervous system diseases.
- Other names
- ADAM23MDC3ADAM 23MDC-3Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3Disintegrin and metalloproteinase domain-containing protein 23
02
Mechanism of action
As a therapeutic target, would likely involve modulation of cell adhesion or integrin-mediated signaling (hypothetical, based on ligand activity with integrins αvβ3)
03
Biological functions
Cell adhesionCell-cell and cell-matrix interactionsNeuronal differentiation and neurogenesisIntegrin binding (specifically as a ligand for αvβ3 integrin)Involvement in nervous system development
04
Disease associations
Cancer (tumor progression, especially of neural origin)Cancer (reported association with tumorigenesis)Epilepsy (Familial temporal lobe epilepsy)Anterograde amnesiaPrognostic marker in kidney renal papillary cell carcinoma
05
Safety considerations
No direct safety data or therapeutic concerns reportedGeneral challenges may include selectivity for nervous system over other tissuesOff-target effects typical for integrin or adhesion molecule modulation
06
Biomarkers
Expression level as a prognostic marker for kidney renal papillary cell carcinoma
Beyond the preview
Go deeper on Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23).